CAGR of 15.0% Projected for Autologous Stem Cell And Non-Stem Cell Based Therapies Market From 2025 to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Autologous Stem Cell And Non-Stem Cell Based Therapies Market Expected to Be in 2029?
The market for autologous stem cell and non-stem cell-based therapies has seen a significant expansion in recent years. It is projected to grow from $9.96 billion in 2024 to $11.49 billion in 2025 with a compound annual growth rate (CAGR) of 15.5%. Factors such as growing prevalence of cancer and diabetes, increase in the elderly population, heightened health awareness, surge in research and development activities, rise in the number of clinical trials, and an uptick in regulatory approval have contributed to this growth during the historic period.
The market for autologous stem cell and non-stem cell based therapies is forecasted to experience a swift expansion in the coming years, increasing to “$20.07 billion by 2029, with a compound annual growth rate (CAGR) of 15.0%.” This anticipated growth during the forecast period can be associated with the escalating incidence of target diseases, a growing elderly population, the rise in neurodegenerative diseases, growing cancer incidences, increasing skin transplantation demands, heightened awareness about regenerative medicine, and collaborations and partnerships amongst prominent players, as well as improved approved therapies reimbursement. Forecast period trends include the utilization of artificial intelligence and machine learning, creation of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, the use of innovative biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, and the incorporation of gene editing technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15729&type=smp
What Are The Contributors To Demand In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
The growth of the autologous stem cell and non-stem cell-based therapies market is predicted to be fueled by the rising demand for personalized treatments. These unique treatments are devised to optimize benefits and reduce undesirable effects according to the distinctive genetics, lifestyle, and preferences of every patient. The augmentation of these customized therapies can be attributed to numerous factors, such as progression in genetics and technology which facilitate more accurate and efficient treatment with minimal side effects, growing patient request for specialized care, plus the probability for saving healthcare costs. By aligning these treatments with individual genetic and health attributes, personalized therapies enhance the effectiveness of autologous stem cell and non-stem cell-based therapies, providing superior outcomes and lesser complications. For example, as per the Personalized Medicine Coalition, a professional membership organization based in the US, the 12 new personalized medicines authorized in 2022 represented roughly 34% of the total new approved therapies, documenting a significant rise compared to preceding years. Consequently, the craving for personalized treatments is escalating the autologous stem cell and non-stem cell-based therapies market.
The autologous stem cell and non-stem cell based therapies market covered in this report is segmented –
1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types
2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications
3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users
Subsegments:
1) By Autologous Stem Cells: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Endothelial Stem Cells
2) By Autologous Non-Stem Cells: Platelet-Rich Plasma (Prp), Adipose-Derived Cells, Peripheral Blood Cells
3) By Other Types: Exosome-Based Therapies, Tissue-Engineered Constructs
What Future Market Trends Are Projected For The Autologous Stem Cell And Non-Stem Cell Based Therapies Industry?
Key players in the autologous stem cell and non-stem cell-based therapy market are advancing with the development of tumor-derived autologous T cell immunotherapy, aiming to improve tailored cancer treatments. This unique form of immunotherapy operates by isolating T cells from a patient’s tumor, cultivating and stimulating them in a laboratory environment, and then reintroducing them into the patient, boosting the immune system’s precision in targeting and eliminating cancer cells. For example, in February 2024, Iovance Biotherapeutics, a biotech company situated in the US, was granted accelerated approval from the US-based federal entity, the Food and Drug Administration, for Amtagvi (lifileucel). This medication, the initial cellular therapy of its kind, is intended for the treatment of adult patients suffering from melanoma. Lifileucel represents a form of tumor-derived autologous T-cell immunotherapy, including a patient’s inherent immune cells known as tumor-infiltrating lymphocytes (TILs). This facilitates the patient’s immune system to identify and combat cancer cells more efficiently.
Who Are The Top-Ranked Companies In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market Today?
Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group
How Is Autologous Stem Cell And Non-Stem Cell Based Therapies Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15729&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
